Ceapro (TSXV:CZO) Debt-to-Revenue : 0.34 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Ceapro Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ceapro's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.40 Mil. Ceapro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$1.85 Mil. Ceapro's annualized Revenue for the quarter that ended in Dec. 2023 was C$6.60 Mil. Ceapro's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.34.

Ceapro Debt-to-Revenue Historical Data

The historical data trend for Ceapro's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Debt-to-Revenue Chart

Ceapro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.26

0.20

0.15

0.14

0.23

Ceapro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.20	0.18	0.33	0.22	0.34

Competitive Comparison of Ceapro's Debt-to-Revenue

For the Biotechnology subindustry, Ceapro's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceapro's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceapro's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ceapro's Debt-to-Revenue falls into.

Ceapro Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ceapro's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.396	+	1.852)	/	9.633
	=	0.23

Ceapro's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.396	+	1.852)	/	6.604
	=	0.34

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Ceapro Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ceapro's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ceapro (TSXV:CZO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

CRPOF:USA

Address

7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2

Website

https://www.ceapro.com

Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines